{"id":"NCT04740827","sponsor":"Allergan","briefTitle":"Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prophylaxis of Migraine in Participants With Episodic Migraine Who Have Previously Failed 2 to 4 Classes of Oral Prophylactic Treatments (ELEVATE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-03-05","primaryCompletion":"2022-08-04","completion":"2022-08-04","firstPosted":"2021-02-05","resultsPosted":"2023-09-21","lastUpdate":"2023-09-21"},"enrollment":315,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Episodic Migraine"],"interventions":[{"type":"DRUG","name":"Atogepant 60 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Atogepant 60 mg","type":"ACTIVE_COMPARATOR"}],"summary":"This study will assess the safety, tolerability, and efficacy of Atogepant 60 mg compared with placebo in participants with episodic migraine and who have previously failed 2 to 4 classes of oral prophylactic treatments.","primaryOutcome":{"measure":"Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in mITT Population","timeFrame":"Baseline to Week 12","effectByArm":[{"arm":"Placebo","deltaMin":-1.86,"sd":0.389},{"arm":"Atogepant 60 mg","deltaMin":-4.29,"sd":0.397}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":114,"countries":["United States","Australia","Canada","Czechia","Denmark","France","Germany","Hungary","Italy","Netherlands","Poland","Russia","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["39982105","39715475","39648617","38364831"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":157},"commonTop":["COVID-19","CONSTIPATION","NASOPHARYNGITIS","NAUSEA"]}}